
ResMed (RMD) Stock Forecast & Price Target
ResMed (RMD) Analyst Ratings
Bulls say
ResMed is supported by a large, underdiagnosed sleep apnea market, with only 20% diagnosis in the US and management believing awareness drivers like GLP-1 prescribing, wearables, and partnerships are bringing more patients into the OSA funnel. Its 1Q27 results showed fundamental strength, with revenue of $1,415m up 5.9% YoY, non-GAAP gross margin of 62.5%, and underlying EPS of $2.91 up 14% YoY, while Americas device growth of 5.5% and Americas mask growth of 10.0% highlighted resilient core demand. The outlook is further underpinned by recurring masks and software revenue, continued market-share gains from product innovation, and strong cash generation that enabled over $1bn of shareholder returns in 1Q27 and guidance for more than $1.85b in FY27.
Bears say
ResMed is facing a negative fundamental setup because foreign exchange is pressuring both profitability and growth, with FX reducing EPS by $0.08 and expected to create a 60 bps revenue headwind in FY27. Cash generation is also weakening, as net operating cash flow fell to $422m in 1Q27 from $457m in 1Q25 and free cash flow declined 10% YoY amid higher inventory and cash tax prepayments, while capex rose to 3.4% of revenue. The downside case assumes a 20–40% fall in devices and masks growth in FY25–26e, and the broader thesis is vulnerable to competitive pressure, weaker healthcare spending, and FDA actions.
This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.
ResMed (RMD) Analyst Forecast & Price Prediction
Start investing in ResMed (RMD)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About ResMed (RMD) Forecast
ResMed (RMD) Analyst Forecast & Price Prediction
Start investing in ResMed (RMD)
Order type
Buy in
Order amount
Est. shares
0 shares